SAINT LAURENT, Quebec, May 11, 2021 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that a significant majority of its shareholders have approved the resolution approving the previously announced investment in IntelGenx by ATAI Life Sciences AG (“atai”), pursuant to which atai will initially acquire an…


Previous articleExploring Oregon’s Measure 110 and The Future of Drug Policy Reform
Next articleMindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development